SOLiD, Inc. (KOSDAQ:050890)
South Korea
· Delayed Price · Currency is KRW | Market Cap | 440.69B |
| Revenue (ttm) | 311.88B |
| Net Income (ttm) | 30.74B |
| Shares Out | 60.29M |
| EPS (ttm) | 506.60 |
| PE Ratio | 14.43 |
| Forward PE | n/a |
| Dividend | 50.00 (0.68%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 697,895 |
| Average Volume | 856,288 |
| Open | 7,490.00 |
| Previous Close | 7,380.00 |
| Day's Range | 7,260.00 - 7,560.00 |
| 52-Week Range | 4,035.00 - 8,600.00 |
| Beta | 0.97 |
| RSI | 60.04 |
| Earnings Date | Aug 13, 2025 |
About SOLiD
SOLiD, Inc. develops, manufactures, and sells parts, products, and equipment for mobile and digital communication networks. The company offers products based on wireless and optical communication technology for hospitals, stadiums, performance halls, universities and office spaces, airports, and subways. The company was formerly known as SOLiD Technologies, Inc. and changed its name to SOLiD, Inc. in April 2012. SOLiD, Inc. was founded in 1998 and is headquartered in Seongnam-si, South Korea. [Read more]
Financial Performance
In 2024, SOLiD's revenue was 331.07 billion, an increase of 3.02% compared to the previous year's 321.36 billion. Earnings were 46.15 billion, an increase of 12.91%.
Financial StatementsNews
Fidus Investment: Solid Q1 Earnings Indicate Resilience For This BDC
Workday: Solid Q1 Revenue, Earnings Beat, Stock Gets Punished For Cautious Guidance — These Analysts Revise Price Target
Workday's Q1 results and Q2 guidance fell short of expectations, causing shares to tank. Analysts remain mostly optimistic with Buy ratings and raised price targets. ... Full story available on Benzin...
Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting
CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, wi...